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Summary A bispecific monoclonal antibody recognising both carcinoembryonic antigen (CEA) and ricin
toxin A chain (RTA) was tested for its ability to target recombinant RTA (r-RTA) to CEA-expressing tumour
cells, alone and in combination with ricin B chain (RTB). The antibody, 636 (Robins et al., 1990), induced
significant RTA cytotoxicity against MKN45 gastric carcinoma cells which express high levels of CEA, using
the r-RTA at a concentration below that known to be intrinsically cytotoxic. The addition of ricin toxin B
chain (RTB) also potentiated cytotoxicity of r-RTA, and there was an additive increase in potentiation against
CEA-positive cells when both RTB and 636 were included. The bispecific antibody restored potentiation by
RTB after blocking of its binding site with excess galactose, and also the cytotoxic activity of whole ricin
which had been blocked with galactose. It was concluded that the 636 bispecific antibody was highly effective
in targeting the toxic moiety of the molecule to CEA-expressing cells, and allowed exploitation of the
additional ability of the B chain to facilitate cellular incorporation. The facilitating function of the B chain
was equally effective whether or not its lectin site was active.
Over the past decade there have been intensive efforts to
exploit anti-tumour monoclonal antibodies for therapeutic
use by using them to target cytotoxic agents to tumour cells.
The greatest interest has been shown in targeted plant or
bacterial toxins, which have the ability to kill eukaryotic cells
in extremely low concentrations (Eiklid et al., 1980). The best
studied of such reagents had been the A chain sub-unit of
ricin toxin (RTA) which has been made selectively cytotoxic
in vitro for various tumour cell lines by chemical conjugation
to a wide range of monoclonal antibodies to form immuno-
toxins (Fitzgerald & Pastan, 1989; reviews in Davies &
Crumpton, 1982; Moller, 1982). Success in vivo has been
more limited for a variety of reasons, notably the inappro-
priate biodistribution of free or conjugated toxins compared
with free monoclonal antibodies (Simmons et al., 1986;
Thorpe et al., 1985; Byers et al., 1987), and their poor tissue
penetration ability. An alternative approach to antibody tar-
geting which may avoid or minimise some of these problems
is to use a monoclonal antibody with dual binding specificity
to link the toxic moiety directly to target cell antigens. This
avoids chemical modification of the toxin and since the
antibody and toxin can be administered separately, the tar-
geting function will depend on the tumour-localising poten-
tial of the antibody alone rather than the less efficient
localisation of the whole complex or conjugate. Toxins
delivered in this way appear to have activity similar to that
of conventional immunotoxins when tested in vitro (Raso &
Griffin, 1981; Webb et al., 1985, 1986; Glennie et al., 1988).
In the case of two-chain toxins such as ricin, it has been
suggested that the non-toxic B chain is involved in the trans-
port of the toxic A chain into the target cell as well as its
function of binding to cell surfaces by means of a lectin site
(Thorpe & Ross, 1982; McIntosh & Thorpe, 1984). Thus it
has been shown that free B chain or B chain 'immunotoxins'
can facilitate the uptake of A chain immunotoxins, rendering
the combination more cytotoxic to target cells than the A
chain immunotoxin alone (McIntosh et al., 1983; Vitetta et
al., 1983, 1984). This report describes the cytotoxic properties
of recombinant RTA (r-RTA) in combination with a bispeci-
fic monoclonal antibody, 636 (Robins et al., 1990), recognis-
ing RTA and carcinoembryonic antigen (CEA), and the
potentiation of this activity by RTB added separately or
included as part of the intact ricin molecule. The antibody
was previously shown to mediate cytotoxicity by a non-toxic
concentration of A chain purified from naturally occurring
ricin, specifically against CEA expressing target cells (Robins
et al., 1990).
Materials and methods
Cell lines
MKN45 human gastric carcinoma cells were grown in mono-
layer culture using RPMI 1640 medium supplemented with
10% foetal calf serum (Gibco-Biocult, Paisley, UK). These
cells express CEA on their surface. Human osteogenic sar-
coma 791T cells, which do not express detectable CEA, were
grown as monolayers in Eagle's minimum essential medium
supplemented with 10% newborn calf serum. Both cell lines
were harvested for assay with a mixture of 0.25% and 0.1%
ethylenediaminetetraacetic acid in phosphate buffered saline
(PBS, pH 7.2). The expression or absence of CEA was con-
firmed at regular intervals by flow cytometry using mono-
clonal antibody NCRC23 which binds to CEA (Price et al.,
1987).
Monoclonal antibody
The bispecific monoclonal antibody 636 was originally
obtained by fusion of hybridomas NCRC23 which secretes
anti-CEA monoclonal antibody, and 596/192 which secretes
monoclonal antibody to RTA (Robins et al., 1990). The
antibody was precipitated from hybrid-hydridoma culture
supernatant by 50% saturation with ammonium sulphate and
dialysed against 0.02 M pH 6.8 phosphate buffer. It was ap-
plied to a hydroxyapatite column and unbound protein was
washed through with 0.02 M buffer, then antibody fractions
were eluted with a 0.02 M to 0.3 M linear gradient of pH 6.8
phosphate buffer at 20 ml h-'. Fractions of 2 ml were tested
for bispecific antibody by ELISA assays and a flow cytomet-
ric bridging assay employing CEA coated beads and fluore-
scein-labelled RTA (Robins et al., 1990).
Reagents
Purified ricin and purified ricin toxin B chain (RTB) were
provided by the XOMA Corporation, Berkeley, CA, USA.
Recombinant RTA (r-RTA) was a gift from Professor M.
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Lord, Department of Plant Biochemistry, University of War-
wick. All reagents were adjusted to the required concentra-
tions in RPMI 1640 + 10% foetal calf serum and sterilised by
0.22 micron filtration prior to use.
Cytotoxicity assay
Cultured tumour cells were plated in 96-well flat bottomed
tissue culture microtiter plates (Falcon 3072, Becton Dickin-
son and Co.) in 0.1 ml of culture medium (RPMI 1640 +
10% foetal calf serum). MKN45 cells were plated at 104 per
well, and 791T at 5 x I03 per well. After 4 h incubation at
37°C to allow attachment, monoclonal antibody at appropri-
ate dilutions was added in 0.05 ml per well. Control wells
received 0.05 ml medium alone. In the standard assay the
cells were incubated a further 30 min, then r-RTA was added
in 0.025 ml medium. This was followed immediately by
0.025 ml RTB or culture medium, as appropriate. Control
wells containing no antibody were treated with r-RTA or
RTB alone, or medium alone. In some assays 0.025 ml whole
ricin was used in place of r-RTA + RTB, and in this case it
was preceded by 0.025 ml galactose at 24 mg ml-' (to give a
final concentration of 3 mg ml 1). In certain assays (Table I)
the addition of RTB was delayed until 4 h after r-RTA, and
cells were washed with culture medium before the application
of r-RTA and before RTB. Washing was accomplished by
completely removing supernatant containing the previously
added reagent, filling the wells with culture medium and
aspirating this medium, followed by replenishment with an
appropriate volume of fresh medium before addition of the
next reagent. Ricin, r-RTA, RTB and 636 antibody were
used at varying concentrations according to the experiment,
to produce the final concentrations indicated in the text in a
total volume of 0.2 ml per well. All treatments were carried
out in quadruplicate. The cells were incubated for 48 h, then
37 KBq 75Se-selenomethionine (0.1 microcuries) in 0.05 ml
medium was added to each well. The cells were incubated
overnight (16 h) during which time the cells in control wells
became confluent. The supernatant was removed and the
cells gently washed under a stream of PBS. The plates were
dried and sealed with a plastic film spray (Nobecutane, Astra
Chemicals) and the wells were separated by means of a band
saw for counting in a gamma spectrometer.
Percent cytotoxicity in treated wells was calculated by
comparing their mean cell survival with that in control wells
treated with culture medium alone, as indicated by 75Se
counts. Significance of differences from control counts or
between different treatments was assessed by Student's t-test.
Table I Cytotoxicity against MKN45 cells mediated by 636 bispecific
antibody, r-RTA and RTB: effect of separating sequential
treatments
% Cytotoxicityb
Treatment a ( s.e.)
250 ng ml' r-RTA only -2.1±2.1
2.5 ngml' RTB only -1.8±4.6
4Jg ml-' 636 only -5.2±5.9
r-RTA; 4 h: RTB 57.5± 6.3
636; 30 min; r-RTA 65.3± 5.2
636; 30 min; wash; r-RTA 75.2±6.5
636; 30 min; r-RTA + RTB 87.6± 6.6
636; 30 min; wash; r-RTA + RTB 93.0±6.4
636; 30 min; r-RTA; 4 h; RTB 87.1±7.0
636; 30 min; wash; r-RTA; 4 h; RTB 92.0±6.9
636; 30 min; wash; r-RTA; 4 h; wash; RTB 87.1 ±6.6
aThe reagents were used at the same concentrations throughout. 636
was always added 30 minbefore r-RTA. Sometimes RTB was added
immediately after r-RTA (r-RTA + RTB) and sometimes 4 h after
r-RTA. Whereindicated, thepreviousreagent wasremovedandthecells
washed before adding the subsequent reagent. b% Cytotoxicity com-
pared with growth in normal culture medium. All combinations of
reagents weresignificantlycytotoxic(P<0.001)although each reagent alone was not.
Results
Cytotoxicity mediated by r-RTA and bispecific antibody 636
Preliminary titrations were carried out to determine the
effects on MKN45 cell survival of r-RTA, RTB, whole ricin
and galactose (data not shown). From this information it was
possible to select concentrations of each reagent which, used
in isolation or in certain combinations, were low enough to
produce no significant cytotoxicity against the target cells.
These concentrations were then used to evaluate the potential
of antibody 636 to augment cytotoxicity against MKN45.
r-RTA was non-toxic at 1 ytgml-', and the chosen dose for
the present experiments was 250 ng protein per ml. At this
RTA concentration five different batches of 636 mediated
highly significant and selective cytotoxicity against MKN45
as previously reported (Robins et al., 1990). Bispecific 636
was frequently used in control wells at up to 8 iLg ml-' in the
absence of r-RTA, and never resulted in cytotoxicity on its
own.
Influence ofB chain on cytotoxicity by r-RTA and 636
Purified RTB was completely non-toxic to cells at a concen-
tration of 1Ong ml-' and was used routinely at 2.5 ngml-'.
When combined at this dose with 250ngml-1' r-RTA the
resultant cytotoxicity was approximately 60% to 70% above
background, indicating a synergistic interaction between the
two ricin fractions. At these concentrations the presence of
636 bispecific antibody produced a modest additive increase
in cytotoxicity, as shown in Figure 1. In this experiment,
added RTB made the non-toxic concentration of r-RTA
significantly cytotoxic for MKN45 cells. Increasing amounts
of antibody also induced cytotoxicity on the part of the
r-RTA, and cytotoxicity of combined r-RTA + RTB was
enhanced by 636 to a degree roughly equivalent to the
enhancement seen with r-RTA alone. When the antibody was
used at a constant concentration of 4fig ml-' and the RTB
was titrated, a similar additive response was observed, up to
the point where the effect of added RTB became maximal
and therefore not subject to further increase (Figure 2). Thus
at RTB concentrations of between 0.0001 and 0.01 ng ml-',
which did not increase RTA cytotoxicity, a constant augmen-
tation to about 35% cytotoxicity occurred due to 636. When
RTB reached an active concentration (1 ng ml-1) the effect of
636 was additive, until augmentation to almost 100% cyto-
toxicity was achieved by RTB alone at 1Ongml-' as well as
by RTB + 636. The antigenic specificity of this additive res-
ponse is shown in Figure 3, where RTB + 636 can be seen to
give greater r-RTA cytotoxicity than RTB against MKN45
cells, while there was no significant difference between
RTB + 636 and RTB in the case of CEA-negative 791T cells.
When r-RTA was titrated against a fixed concentration of
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Figure 1 Titration of 636 against r-RTA (250 ngml-') + RTB
(2.5 ngml-'). (0) r-RTA alone, (0) r-RTA + RTB. Cells were
MKN45. Vertical bars indicate standard errors of means. RTB
enhanced cytotoxicity above levels achieved with r-RTA alone,
and 636 resulted in additive potentiation at all concentrations
(P<0.001).
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Figure 2 Titration of RTB against r-RTA (250 ngml-') and 636
(41ig ml-'). (0) r-RTA alone, (0) r-RTA + 636. Cells were
MKN45. Vertical bars indicate standard errors. 636 enhanced
cytotoxicity above levels achieved with r-RTA alone, and RTB
resulted in additive potentiation between 0.1 ngml-' and maxi-
mum % cytotoxicity (P<0.001 at 1 ngml-').
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Figure 3 Specificity of combined potentiation of r-RTA (250 ng
ml1 ') by 636 (2.5 sg ml-') and titrated RTB. (U) MKN45 + 636,
(0) MKN45 without antibody, (0) 791T + 636, (0) 791T with-
out antibody. Vertical bars indicate standard errors. Cytotoxicity
against both cell lines was potentiated by RTB above 0.1 ng ml- ',
but the effect of 636 alone or combined with RTB was seen only
with MKN45 (P<0.001 comparing MKN45 + 636 with 791T +
636).
RTB (2.5 ng ml-') or RTB (2.5 ng ml-') plus 636 (8 gsg ml-')
using MKN45 cells, additive responses of 636 and RTB were
again seen (Figure 4). The r-RTA was titrated from 100 ng
ml-' downwards, and at these concentrations augmentation
of cytotoxicity by 636 was less pronounced than at 250 ng
ml- RTA. However, RTB was more effective than 636
alone, and a mixture of 636 and RTB was the most effective
treatment.
Effect ofseparating sequential treatments
In some assays RTB treatment was delayed until 4 h after the
addition of r-RTA to 636-coated cells, and in these experi-
ments a comparison was made between cultures which were
washed after 30 min incubation with 636, but before addition
of r-RTA, and after 4 h r-RTA incubation but before addi-
tion of RTB, and cultures which received no washing or
removal of the previous reagent before application of the
next in the sequence (Table I).
In these tests both 636 at 4 ggml-I and RTB at 2.5 ng
ml-' again significantly enhanced r-RTA cytotoxicity (P<
0.001), and the combination of 636, r-RTA and RTB was
more effective than treatment with 636 + r-RTA (P<0.025)
or r-RTA + RTB (P<0.01). Combined 636, r-RTA and
RTA concentration (ng ml-')
Figure 4 Titration of r-RTA against RTB (2.5 ngml-'), 636
(8 sgml1'), or RTB (2.5 ngml-') + 636 (8jgml-'), using
MKN45 target cells. Mean cytotoxicity of r-RTA alone over the
range 0.0l-lOOngml[l was -1.4%. (0) 636, (0) RTB, (0)
RTB + 636. Vertical bars indicate standard errors. r-RTA cyto-
toxicity for MKN45 followed the pattern RTB+636>RTB>
636; the effects of RTB and 636 together were additive. At
I ngml- r-RTA, RTB + 636 vs RTB P<0.05 and RTB + 636
vs 636 P<0.02; at IO ngml-I r-RTA, RTB + 636 vs RTB P<
0.05 and RTB+636 vs 636 P<0.01; at lOOngml-l r-RTA,
RTB + 636 vs RTB P<0.05, RTB + 636 vs 636 P<0.001, and
RTB vs 636 P<0.01.
RTB was equally effective whether RTB was added immedi-
ately after r-RTA or 4h later, and whether or not the
previous reagent was removed and the cells washed at any or
all of the reagent addition steps. None of the modifications
produced results significantly different from the standard
procedure in which all the reagents remained present until
termination of the assay. This indicates that adequate 636
binding to MKN45 could occur within 30 min, and that
accumulation of sufficient r-RTA/636 complex on (or in) the
target cells was completed within the next 4 h. Furthermore,
the enhancement of its internalisation and subsequent cyto-
toxic action by RTB was not dependent on reassociation of
free r-RTA and RTB in the culture medium.
Effect of636 on cytotoxicity ofgalactose-blocked ricin
Galactose at high concentrations was inhibitory to MKN45
cells, but at 3 mgml1' (0.16 mM) it was virtually non-inhibi-
tory and was sufficiently in excess of lectin sites on the B
chain to reduce the cytotoxicity of 1 ngnml- whole ricin to
about 5%. In the absence of galactose the 50% inhibitory
concentration of ricin for MKN45 was about 0.1 ngml-',
and cytotoxicity at 1 ngml' was almost 100%. Titration of
636 against galactose-blocked ricin at 1 ngml-' produced
increasing cytotoxicity against MKN45, until at 4;Lgmlml
antibody it was restored to about 80% of the level seen with
native ricin (Figure 5). Purified RTB (2.5 ngml-') was
similarly blocked with 3 mgml-' galactose and tested in
combination with r-RTA (250ngnml') and titrated 636, as
also shown in Figure 5. The previously demonstrated ability
of RTB to augment r-RTA cytotoxicity was abolished by
galactose, but full cytotoxic activity was restored in the
presence of increasing amounts of 636.
The relative cytotoxic activities of r-RTA, blocked ricin
and r-RTA + blocked RTB in the absence of 636 and in the
presence of the highest 636 concentration tested (8 gml-1)
are compared in Figure 6. This comparison puts into per-
spective the role of B chain in facilitating A chain cytotox-
icity. Targeting with 636 antibody was effective with r-RTA
alone, but the presence of an adequate amount of blocked B
chain (either as part of intact ricin or as added RTB at 1%
of the r-RTA concentration) significantly enhanced the
efficiency of r-RTA targeting.
Discussion
Bispecific antibodies capable of targeting toxic moieties to
tumour cells in vitro have been produced by chemical hydro-BISPECIFIC ANTIBODY AND RICIN FRACTIONS 673
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Figure 5 Effect of 636 on cytotoxicity of galactose-blocked ricin
(1 ng ml-') and r-RTA (250 ng ml1) + galactose-blocked RTB
(2.5 ng ml-') against MKN45 cells. (0) blocked ricin, (l)
r-RTA + blocked RTB. Vertical bars indicate standard errors.
Both responded highly significantly (P<0.001 at or above
0.25 gg ml-' 636).
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Figure 6 Comparison of augmented cytotoxicity against
MKN45 using 8 pg ml-' 636 antibody. ( ) r-RTA (250 ng
ml-'), (LII) galactose-blocked ricin (1 ng ml-'), (m) r-RTA
(250 ng ml-') + galactose-blocked RTB (2.5 ng ml-'). Vertical
bars on the histograms indicate standard errors. Cytotoxicity of
all reagents was augmented by 636 compared with background
(P<0.001), but augmentation was greater with blocked ricin or
r-RTA + blocked RTB than with RTA alone (P<0.001).
lysis and reconstitution of two parental antibodies (Raso &
Griffin, 1981; Glennie et al., 1988) and by production of
hybridomas secreting monoclonal antibodies with dual speci-
ficity (Webb et al., 1985, 1986; Corvalan & Smith, 1987;
Pimm et al., 1990). In studies in which the toxic molecule was
a plant toxin such as gelonin (Glennie et al., 1988) or RTA
(Webb et al., 1985, 1986), the reported efficiency of targeting
by bispecific antibodies was comparable with that commonly
observed with conventional immunotoxins in which toxin
and anti-tumour monoclonal antibody are linked chemically
(Davies & Crumpton, 1982; Moller, 1982). In the case of
bispecific antibody 636, significant cytotoxicity against
MKN45 could be achieved at an RTA concentration as low
as 4 x 10-9 M (Robins et al., 1990), which compares with
independent experiments performed with chemically prepared
conjugates between RTA and a different CEA-specific anti-
body (228), in which the most active conjugates killed 50%
of MKN45 cells at a concentration of about 1.5 x 10-9 M
RTA (Byers et al., 1988). The augmentation of RTA activity
by 636 was specific for CEA expression cells, and was depen-
dent upon the dual specificity of the antibody; parental anti-
CEA and anti-RTA monoclonal antibodies had no effect at
all (Robins et al., 1990).
The cytotoxicity of RTA immunotoxins can be enhanced
in several ways, notably the addition of lysosomotropic
agents such as amines or proton ionophores or administra-
tion of RTB. Lysosomotropic agents appear to act by raising
the pH of endosomes (Sandvig & Olsnes, 1982; Wileman
et al., 1985). This can result in the increased release of ricin
following internalisation of ricin-ligand complexes, and it is
possible that RTA is released from internalised immunotox-
ins in a similar manner. RTB can be administered in free
form, or conjugated to the same targeting antibody as the
RTA immunotoxin or any antibody recognising the immuno-
toxin conjugate (McIntosh et al., 1983; Vitetta et al., 1983,
1984), and is thought to aid cellular incorporation of
immunotoxin by facilitating translocation through the cell
membrane (McIntosh & Thorpe, 1984). In cases where the
targeted antigen is rapidly and efficiently internalised by
the cell the lack of B chain may be advantageous but non-
essential, but there are instances in which RTA immunotoxin
is not readily incorported and the transport function of the
B chain then becomes of major importance (McIntosh et al.,
1983; Eccles et al., 1987). Hence the continued interest
in facilitation of immunotoxin uptake by extraneous B
chain.
The reason for removing the B chain before conventional
immunotoxin preparation is that its lectin site (binding to
cellular galactose residues) is quantitatively much more
effective at binding to cells and delivery of A chain than a
conjugated antibody, and this would overcome and negate
any selectivity contributed by the antibody. It is possible,
however, to block lectin activity of whole ricin conjugates
with excess lactose or galactose, or to select intrinsically
blocked whole ricin conjugate molecules by chromatography
(Thorpe & Ross, 1982; Gregg et al., 1987; Cattel et al., 1988).
Galactose blocking can be very effective in aiding selectivity
of ricin-antibody conjugates in vitro, and a galactose-blocked
ricin anti-iodiotype antibody conjugate has been tested in
vivo against a guinea pig B cell leukaemia line (Gregg et al.,
1987). The blocked ricin conjugate was therapeutic at 100-
fold lower concentration than an equivalent RTA immuno-
toxin, but was also 100 times more toxic at equimolar doses,
so that the overall therapeutic index was the same for both
reagents.
The mechanism of action of RTB in potentiating RTA
uptake has not been established. One assumption is that A
and B chains reassociate to form intact toxin (McIntosh &
Thorpe, 1984) which then presumably acts at the target site.
In the present studies r-RTA was used at a standard concen-
tration of about 8 x 100- M, and RTB at a concentration of
only 1% of this, so most of the r-RTA could not be involved
in reassociation. If, however, all the RTB had reassociated
with r-RTA on an equimolar basis, the resultant 'reconsti-
tuted ricin' could have been present in a quantity more than
adequate to kill 100% of the target cells. Further titration of
RTB (Figure 2) or r-RTA (Figure 4) resulted in loss of
cytotoxicity and this may have been due to the diminished
potential for adequate reassociation. However, if full recon-
stitution had taken place under the standard conditions one
would expect the resultant cytotoxicity to over-ride any aug-
menting effect of the 636 antibody. The fact that the cell kill
was low enough to detect 636 augmentation of r-RTA +
RTB cytotoxicity at the concentrations used in Figures 1 and
2, and that it was specific for CEA-positive cells (Figure 3)
suggests that complete reassociation did not occur. Never-
theless, it is probable that partial reassociation is involved in
potentiation of cytotoxicity, and the maximal cytotoxicity
values observed in Figures 2 and 3 at the highest RTB
concentration might be accounted for by the accumulation of
sufficient recombined toxin. The experiments in which excess
636 and r-RTA were removed before RTB was applied to the
cells (Table I) suggests that if reassociation is necessary, it
can occur at the target cell site, and the formation of free
ricin in the supernatant culture medium is not required. RTB
augmentation ofcytotoxicity was equally high in washed cells
as in those which were left in continuous contact with 636,
r-RTA and RTB for a further 60 h.
Opinion is divided on whether or not an active lectin
binding site is required for augmentation to occur. This
cannot satisfactorily be resolved by studying chemically link-
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ed immunotoxins, because the need to avoid lectin activity is
fundamental to their design, and in published studies of the
effect of RTB or RTB conjugates on RTA immunotoxins the
B chain lectin site has not been blocked (McIntosh et al.,
1983; Eccles et al., 1987; Vitetta et al., 1983, 1984). The
experiments shown in Figure 5, however, address this ques-
tion. Whole ricin inactivated by blocking its B chain lectin
site with galactose was rendered highly cytotoxic by the
addition of 636 bispecific antibody, and there is no doubt
that the B chain played an important role in this because the
ricin was used at approximately 20 times lower molarity than
the lowest concentration of RTA required for 636-mediated
cytotoxicity (Robins et al., 1990). A mixture of intact RTB
and r-RTA at the concentrations shown in highly cytotoxic,
presumably because the RTB reassociates with sufficient r-
RTA and mediates its entry into the cell by binding via the
lectin site. When the lectin site was blocked with galactose as
in Figure 5, cytotoxicity was lost owing to the lack of
binding ability. However, addition of 636 to induce binding
of r-RTA to the cells restored the augmented level of
cytotoxicity characteristic or r-RTA + unblocked RTB + 636.
These results suggest that the B chain translocation function
is still active when the lectin site is blocked, and therefore
that the lectin site is not involved. This is in agreement with
results of studies using intrinsically blocked whole ricin-
antibody conjugates (Cattel et al., 1988). A blocked ricin
immunotoxin had cytotoxic activity as high as that of an
unblocked ricin conjugate, but was much more selective than
the unblocked reagent. An RTA immunotoxin showed the
same high selectivity, but was much less toxic than the
blocked ricin conjugate.
The studies reported here demonstrate that a bispecific
monoclonal antibody can provide an effective means of
targeting r-RTA in vitro, and that the cytotoxicity observed is
able to be potentiated by the addition of RTB. Moreover, the
RTB is not required to possess an active lectin site. On
theoretical grounds, there may be advantages to such a com-
bination in comparison with a conventional immunotoxin
when applied in vivo in a therapeutic context. The bispecific
antibody may localise at the tumour site more efficiently than
an RTA-antibody or blocked ricin-antibody conjugate, which
is likely to be rapidly cleared from the circulation (Simmons
et al., 1986; Byers et al., 1987). Subsequently administered
RTA may then be trapped by the pre-localised antibody in
higher quantities, before elimination, than could be delivered
as an immunotoxin, particularly if recombinant RTA (lack-
ing carbohydrate side chains) is used. Also, the possibility of
using lectin-inactivated B chain to enhance the effect of
localised A chain may be a safer approach than using intact
B chain which could conceivably recombine with A chain to
form active ricin. These potential advantages now require to
be evaluated in a therapeutic model.
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